PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src.

＞98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

PD 173074；PD-173074；FGF/VEGF Receptor Tyrosine Kinase Inhibitor

White to light yellow powder

Ethanol ：52.4 mg/mL (100 mM)

DMSO ：52.4 mg/mL (100 mM)

FGFR1,VEGFR2

PD 173074 inhibits autophosphorylation of FGFR1 in a dose-dependent manner with an IC50 in the range 1-5 nM. PD 173074 is an ATP-competitive inhibitor of FGFR1 with an inhibitory constant (Ki) of 40 nM. PD 173074 and SU 5402 produce concentration-dependent reductions in FGF-2 enhancement of granule neuron survival, with IC50 values of 8 nM and 9 μM, respectively. PD 173074 does not inhibit neurotrophic and neuritogenic actions of FGF-2 signalling molecules in cerebellar granule neurons. PD 173074 and SU 5402 concentration-dependently inhibits the neurite growth response, when tested on FGF-2-treated granule neurons growing on polylysine/laminin, with IC50s of 22 nM and 25 μM, respectively. PD173074 effectively antagonizes the effect of FGF-2 on proliferation and differentiation of OL progenitors in culture. Mitogen-activated protein kinase (MAPK) activation, a downstream event after activation of either FGFR or PDGFR, is also blocked by PD173074 in OL progenitors stimulated with FGF-2 but not PDGF.

PD 173074 (1 mg/kg, i.p.) exhibits dose-dependent inhibition of FGF-induced neovascularization and angiogenesis in mice. D173074 (25 mg/kg, p.o.) significantly inhibits tumor growth in mice.

[1] Mohammadi M, et al. EMBO J, 1998, 17(20), 5896-5904.

[2] Skaper SD, et al. J Neurochem, 2000, 75(4), 1520-1527.

[3] Bansal R, et al. J Neurosci Res, 2003, 74(4), 486-493.

[4] Trudel S, et al. Blood, 2004, 103(9), 3521-3528.

[5] Pardo OE, et al. Cancer Res, 2009, 69(22), 8645-8651.

[6] Byron SA, et al. Int J Gynecol Cancer, 2012, 22(9), 1517-1526.